Clinical features and health-related quality of life in adult patients with mucopolysaccharidosis IVA: the Spanish experience

Pilar Quijada-Fraile1*, Elena Arranz Canales2, Elena Martín-Hernández1, María Juliana Ballesta-Martínez3,4, Encarna Guillén-Navarro3,4, Guillem Pintos-Morell5, Marc Moltó-Abad6, David Moreno-Martínez5,6, Salvador García Morillo7, Javier Blasco-Alonso8, María Luz Couce9, Ricardo Gil Sánchez10, Elisenda Cortès-Saladelafort11, Mónica A. López Rodríguez12, María Teresa García-Silva1 andMontserrat Morales Conejo2

Abstract

Background: Mucopolysaccharidosis (MPS) IVA or Morquio A syndrome is a progressive and disabling disease characterized by a deficiency of the enzyme N-acetylgalactosamine-6-sulphate sulphatase. Its clinical presentation is very heterogeneous and poorly understood in adults.

The aim of this study was to describe the clinical manifestations of MPS IVA in adult patients in Spain and to assess their health-related quality of life (HRQoL).

Results: Thirty-three patients from nine reference centres participated in the study. The median age was 32 (interquartile range [IQR]: 20.5–40.5) years. The phenotype was classical in 54.5% of patients, intermediate in 33.3% of patients, and non-classical in 12.1% of patients. The most common clinical manifestation was bone dysplasia, with a median height of 118 (IQR: 106–136) cm. Other frequent clinical manifestations were hearing loss (75.7%), ligamentous laxity (72.7%), odontoid dysplasia (69.7%), limb deformities that required orthopaedic aids (mainly hip dysplasia and genu valgus) (63.6%), and corneal clouding (60.6%). In addition, 36.0% of patients had obstructive sleep apnoea/hypopnoea syndrome and 33.3% needed non-invasive ventilation. Cervical surgery and varisation osteotomy were the most common surgical interventions (36.4% each). Almost 80% of patients had mobility problems and 36.4% used a wheelchair at all times. Furthermore, 87.9% needed help with self-care, 33.3% were fully dependent, and 78.8% had some degree of pain. HRQoL according to the health assessment questionnaire was 1.43 (IQR: 1.03–2.00) in patients with the non-classical phenotype, but 2.5 (IQR: 1.68–3.00) in those with the classical phenotype. Seven patients were initiated on enzyme replacement therapy (ERT), but two of them were lost to follow-up. Lung function improved in four patients and slightly worsened in one patient. The distance achieved in the six-minute walk test increased in the...
Background
Mucopolysaccharidosis (MPS) IVA or Morquio A syndrome (OMIM 253000) is a progressive and disabling disease. It is an inherited lysosomal disorder caused by pathogenic variants in the GALNS gene, which codes for the N-acetylgalactosamine-6-sulphate sulphatase enzyme. According to data from the Human Gene Mutation Database Professional, 348 pathogenic variants had been reported until August 2019 [1], and more than 70% were missense/nonsense mutations [2]. This disorder leads to impaired lysosomal degradation of the glycosaminoglycans (GAGs) keratan sulphate and chondroitin-6-sulphate, which alter cell function. The clinical manifestations of MPS IVA reflect the tissue distribution of keratan sulphate and chondroitin-6-sulphate [3].

Although bone dysplasia is the most typical feature, it is a multisystemic disease, with both skeletal and non-skeletal symptoms. The clinical presentation of MPS IVA is widely heterogeneous, from the classical phenotype, through the intermediate phenotype, to the non-classical phenotype [4]. This phenotypic variability is related to the high diversity of GALNS mutations [5, 6]. The traditional classification of MPS IVA is subjective, and the disease should be considered as a continuum [7]. Skeletal symptoms include bone deformities, short stature, and gait disturbances, as well as genu valgum, ligamentous laxity and kyphosis, among others [3]. Non-skeletal symptoms are due to GAG storage in areas such as the ear, cornea, teeth, cardiac valves, upper airways, and liver [4].

The diagnosis of MPS IVA is initiated by the recognition of clinical and radiological features, and then the following laboratory tests can be performed: a biochemical test (total urine GAGs), an enzymatic test (N-acetylgalactosamine-6-sulphate sulphatase activity) and molecular analysis [2, 3].

Treatment of MPS IVA was symptomatic only until the availability of ERT with elosulfase alfa (Vimizim®, BioMarin Pharmaceutical Inc., San Rafael, CA, USA), which was approved by both the US Food and Drug Administration and the European Medicines Agency in 2014. In a long-term study, endurance improved in patients treated with elosulfase alfa [8]: 26 patients (17 adults and nine patients younger than 18 years) showed general improvement in both endurance in the six-minute walk test (6MWT) and the performance of activities of daily living (ADL) during the first year of treatment. These improvements increased or stabilized over a follow-up of up to seven years [9].

In Spain, paediatric patients with MPS IVA are managed by paediatric specialists in clinics devoted to congenital metabolic diseases and/or skeletal dysplasias. However, it has proved difficult for paediatric patients with MPS to access appropriate long-term follow-up on reaching adulthood, despite several initiatives to improve transition from paediatric to adult care for these patients [10]. Knowledge on the clinical evolution of MPS IVA in adults is limited, partly because of the low prevalence of the disorder, and partly because of the absence of reference centres in Spain in the past. The recent creation of such reference centres for adult patients with inherited metabolic diseases in Spain will improve our understanding of the natural history of MPS IVA.

It has been suggested that hematopoietic stem cell transplantation (HSCT) could be useful in MPS IVA. However, based on current evidence, it cannot be recommended [11].

The quality of life of patients with rare diseases has not been extensively assessed [12], but one large study showed that health-related quality of life (HRQoL) was lower in patients with rare diseases than in patients with other chronic diseases [13].

The objectives of the present study were therefore to describe the clinical characteristics of adult patients with MPS IVA in Spain, and to assess the burden of disease and the HRQoL in these patients.

Results
Sociodemographic and diagnostic data
Conducted between May 2018 and May 2019, the study included 33 adult patients from nine tertiary hospitals in Spain. All the questionnaires sent were completed and returned.

Table 1 shows the sociodemographic and diagnostic data of the study population. Patients aged between 16 and 65 years (median 32), and more than half (51.5%) were male.
Urinary GAGs were measured in 18 patients (54.5%), either at diagnosis (16 patients, 48.5%) or later (2 patients, 6.1%), and were found to be elevated in all them. In addition, enzyme activity was analysed in 16 patients (48.5%). Although measurement methods and reference values differed between laboratories, enzyme activity was reduced in all these patients (data not shown).

Genetic variants of GALNS were analysed in 16 patients (48.5%). The most common GALNS mutation was the missense mutation c.1156C > T, which was found in eight (24.2%) patients (six of whom were homozygous), all with classical phenotype. Another frequent GALNS mutation was c.901G > T, found in 4 patients (12.1%), with 2 patients with classical phenotype and 2 patients with intermediate phenotype. It was also common the mutation c.761A > G, found in two patients (6.1%) (both homozygous and with intermediate phenotype).

Weight and length at birth were normal in the 11 patients with data available. Patients had been diagnosed during childhood and the most common clinical feature at diagnosis was bone dysplasia. More than half (54.5%) the patients had the classical phenotype (Table 1). These patients were shorter than those with intermediate or non-classical phenotypes were.

### Clinical manifestations

All patients had typical clinical manifestations of Morquio A disease: skeletal dysplasia, including dwarfism with short trunk and neck; pectus carinatum; genu valgum; and joint deformities. Height and weight were low (Table 1). Figure 1 shows common clinical manifestations other than bone dysplasia according to the phenotypes.

### Lung function

Lung function was assessed in only 22 patients, as some were unable to perform the tests because of difficulty with the technique. Basal oxygen saturation was measured in 20 patients and found to be normal in all of them. However, obstructive sleep apnoea-hypopnoea syndrome was shown in 12 patients (36.4%), 11 of whom needed non-invasive ventilation (biphasic positive airway pressure in one patient; nocturnal biphasic positive airway pressure in four patients; and nocturnal continuous positive airway pressure in six patients). Another patient required tracheostomy.

With regard to lung function tests, the median forced expiratory volume in 1 s was 840 (435–1470) mL and the median forced vital capacity was 1020 (515–1675) mL. FEV1/FVC expressed as percentage was 77.50 (72.70–84.69) in patients with classical phenotype, 89.98 (86.71–92) in patients with intermediate phenotype, and 89.98 (86.1–92) in patients with non-classical phenotype.

### 6MWT

Most patients were unable to perform the 6MWT, with only eight patients completing the test. The median walking distance was 263.5 (140.3–436.5) m.

### Results in patients treated with ERT

Seven patients, all them with classical phenotype, were initiated on ERT therapy. However, 2 patients were lost to follow-up. In 5 patients, treatment was started younger than 20 years of age. The dose administered was 2 mg/kg by intravenous infusion over 3.5–4.5 h or longer.

At the last visit of the study, lung function had improved in 4 patients and slightly worsened in 1 patient. The walking distance in the 6MWT increased in the

---

**Table 1** Sociodemographic and diagnostic variables in a population of adult patients with MPS IVA in Spain

| Variable                          | Value (N = 33) |
|----------------------------------|---------------|
| **Age, median (IQR), years**     | 32 (20.5–40.5) |
| **Sex, n (%)**                   |               |
| Men                              | 17 (51.5)     |
| Women                            | 16 (48.5)     |
| **Height, median (range) (cm)**  |               |
| Men                              | 126 (113.7–142.5) |
| Women                            | 116 (105.2–124.7) |
| **Weight, median (range) (kg)**  |               |
| Men                              | 35.5 (30.9–49.7) |
| Women                            | 31 (25.4–36.7) |
| **Phenotype**                    |               |
| Classical                        | 18 (54.5)     |
| Intermediate                     | 11 (33.3)     |
| Non-classical                    | 4 (12.1)      |
| **BMI (kg/m²)**                  |               |
| Classical phenotype              | 21.36 (18.23–25.30) |
| Intermediate phenotype           | 24.68 (23.36–31) |
| Non-classical phenotype          | 20.03 (16.31–26) |
| Consanguinity history, n (%)     | 3 (9)         |
| Patients with affected siblings, n (%) | 12 (36.6) |
| Age at diagnosis, years (IQR)    | 5.5 (2–12.6)  |
| **GAGs, mg/mmol creatinine (IQR)** | 22.60 (6.81–29.01) |
| **Common GALNS mutations, n (%)**|               |
| c.1156G>C=T                      | 8 (24.2) [6 patients were homozygous] |
| c.901G>T                         | 4 (12)        |
| c.761A>G                         | 2 (6) [both patients were homozygous] |
| **First symptom at diagnosis, n (%)** |   |
| Bone dysplasia                   | 8 (24.2)   |
| Kyphoscoliosis                   | 5 (15.1)     |

GAGs, glycosaminoglycans (keratan sulphate and chondroitin-6-sulphate); IQR, interquartile range; MPS, mucopolysaccharidosis
four patients who could perform the test (Table 2). All patients treated with ERT reported a reduction in pain, although height was similar in these patients to that of patients who did not receive ERT.

**Surgical interventions**

The two most common surgical interventions were cervi-
cal surgery and knee varisation osteotomy. Other surgical
interventions were surgery for hip dysplasia, adenoidec-
tomy and/or tonsillectomy, transtympanic drainage, and
heart valve surgery (Fig. 2). Results of surgical interven-
tions were not satisfactory in all patients.

**Burden of disease**

Table 3 gives details of the burden of disease. Accord-
ing to the results of the study questionnaire, almost 80%
of patients had mobility problems, with more than 40% being severe problems. More than 65% of patients used
a wheelchair, with more than one-third of patients needing
to use one at all times. Almost all patients needed help with self-care, and one-third of patients were unable
to take care of themselves. More than 75% of patients
needed help to perform ADL, with one-third being fully
dependent.

Also according to the results of the study question-
naire, more than 80% of patients reported some degree
of pain and almost 25% of patients had anxiety/depres-
sion. Pain was worse in patients who were permanently

---

**Table 2 Results in patients with MPS IVA treated with elosulfase alfa**

| Patient number | Time on ERT, years | FVC (mL) | FEV₁ (mL) | 6MWT (m) |
|----------------|-------------------|----------|-----------|----------|
|                |                   | Before ERT | Last visit | Before ERT | Last visit | Before ERT | Last visit |
| 1              | 1                 | 1663      | 1610      | 1361      | 1358      | 125        | 150        |
| 2              | 1                 | 1430      | 1452      | 1148      | 1154      | 39         | 86.4       |
| 3              | 6                 | 938       | 1318      | 896       | 1068      | 32         | 424        |
| 4              | 4                 | 2460      | 2690      | 2180      | 2360      | –          | –          |
| 5              | 4                 | 780       | 870       | 680       | 730       | 302        | 351        |

6MWT, six-minute walk test; ERT, enzyme replacement therapy; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity
in a wheelchair. Only five patients had a job (four of them working part-time) and only six patients lived independently.

Twenty-one patients completed the health assessment questionnaire (HAQ). The median score was 2.12 (range 1.62–3.00). However, HRQoL scores differed according to phenotype: the median HAQ score was 1.43 (range 1.03–2.03) in patients with non-classical phenotype, but 2.44 (range 1.62–3.00) and 2.5 (range 1.68–3.00) in patients with the intermediate and classical phenotypes, respectively. Furthermore, HRQoL was generally better in patients treated with ERT, with a median of 1.75 (range 1.25–2.34) versus 2.25 (range 1.62–3.00) in patients who did not receive ERT.

**Discussion**

We gathered data from 33 adult patients with MPS IVA. As the questionnaire return rate was 100%, this number of patients is probably very close to the whole population of MPS IVA adult patients in Spain, although there may be a number of patients who are undiagnosed.

The median age at diagnosis was 5 years, which concurs with data in the International Morquio A Registry in 2007 [4]. More than one-third of our patients had affected siblings, possibly because genetic counselling and prenatal testing were more difficult to obtain years ago than nowadays, or even unavailable.

More than 50% of our patients had the classical phenotype. We did not examine the relationship between phenotype and GALNS mutations, and genetic analysis was available for only 16 patients. However, we found two GALNS mutations that have been associated with classical phenotype (c.1156C > T and c.901G > T) [14]. It would be interesting to assess such relationship in a future study with more complete genetic data available.

**Table 3** Burden of disease in a population of adult patients with MPS IVA in Spain

| Variable                        | Value, n (%) (N = 33) |
|---------------------------------|------------------------|
| Mobility problems               | 26 (78)                |
| Mild                            | 9 (27.3)               |
| Moderate                        | 3 (9)                  |
| Severe                          | 14 (42.2)              |
| Wheelchair use                  | 22 (66.7)              |
| Always                          | 12 (36.4)              |
| Need help with self-care        | 29 (87.9)              |
| Fully dependent                 | 11 (33.3)              |
| Need help with daily activities | 25 (75.7)              |
| Mild help                       | 6 (18.2)               |
| Moderate help                   | 8 (24.2)               |
| Fully dependent                 | 11 (33.3)              |
| Pain                            | 26 (78.8)              |
| Mild                            | 13 (39.4)              |
| Moderate                        | 9 (27.3)               |
| Severe                          | 4 (12.1)               |
| Anxiety/depression              | 8 (24.2)               |

MPS, mucopolysaccharidosis
**Clinical manifestations**

With regard to the clinical manifestations of MPS IVA, height was under the third percentile in most patients—short stature is common in MPS IVA patients [4]. As expected, length and weight were normal at birth.

Another common clinical manifestation was ligamentous laxity, which can complicate personal care and activities such as getting dressed. It can also make writing difficult, which can be a problem for work or study.

Other non-skeletal manifestations, such as corneal clouding and respiratory compromise, were frequent in our patient population, correlating with findings in other studies [4, 15]. We found that up to one-third of patients needed non-invasive ventilation. This finding highlights the relevance of periodic respiratory check-ups in patients with MPS IVA.

Hearing loss is also common in MPS IVA. Patients suffer frequent otitis and middle and inner ear abnormalities, which cause mixed hypoacusis at around 5 years of age [3]. More than 75% of patients with MPS IVA in our study had hearing loss, a percentage similar to that found in the Morquio A Clinical Assessment Program study [15].

**ERT**

In our study, five of the seven patients who began ERT did so before the age of 18 years under an early access programme [16]. Two patients left the country and were lost to follow-up, meaning we had data from only five patients treated with elosulfase alfa. This small number of patients meant that it was not possible to perform an in-depth analysis of the potential effects of ERT. However, in one study of 37 adult patients with MPS IVA treated for 120 weeks with elosulfase alfa, endurance increased and performance of ADL improved, without changes in pulmonary function [17]. However, in 10 patients with more severe disease and limited mobility treated with elosulfase alfa for 48 weeks, results were inconsistent because of clinical heterogeneity of patients, severe deformities, and the small sample size [18]. Nevertheless, in a study with 5-year follow-up, elosulfase alfa prevented disease progression [19]. Moreover, performance of ADL improved after 120 weeks of ERT in 170 patients [20].

**Surgery**

The percentages of surgical intervention were similar to those found in the International Morquio A Registry in 2007, in which 50% of patients underwent cervical surgery, 30% ear surgery, 26% limb surgery and 25% hip surgery [4]. Orthopaedic surgery in patients with MPS IVA should be considered individually, assessing risk, timing, pain, and patient preferences [11].

**Burden of disease**

Patients with MPS IVA had reduced mobility [4, 15, 21]. In our study, almost 80% of patients had problems for walking, and more than 65% needed a wheelchair some or all the time. It should be noted that wheelchair use has been related to worse HRQoL [22]. Furthermore, as shown in our study, patients with MPS IVA need help with self-care and performing ADL [22].

Another common symptom in patients with MPS IVA is pain, which is related to musculoskeletal problems. Pain can affect the spine, the upper and lower extremities, and the head and neck, and can interfere with mobility and ADL. In our study, almost 80% of patients reported some degree of pain. Similarly, in a patient-reported outcomes survey, 74% of adults reported joint pain [22]. Pain was more severe in wheelchair users than in non-users and was worse in patients who used a wheelchair all the time compared with those who used a wheelchair intermittently, in contrast with other published results [22].

Psychological symptoms can go unnoticed because of the severity of physical symptoms. However, many patients with MPS have some degree of psychological disturbance [23], with more than 50% of patients with MPS IVA having psychological symptoms in one study [24]. We found that 20% of patients symptoms of anxiety, but we did not use a specific questionnaire for mental health. Therefore, this percentage is not conclusive.

The high burden of disease in our study could be partly because 60% of our patients had not been cared for at paediatric reference units when they were children/teenagers, being managed instead at trauma and orthopaedic clinics because of the bone dysplasia, but without specific follow-up of the other disease features. In addition, the transition from paediatric to adult units is not always well managed in Spain.

Various factors relating to surgery are also probably implicated in the high disease burden. First, the number of surgical procedures was insufficient. Second, surgical outcomes were not as good as expected or desired, perhaps because some procedures were performed at non-specialist centres. In general terms, these patients may not have received optimal healthcare because of the severity of their disease and the absence of referral to specialist centres. This, together with a lack of co-operation from some patients not happy with the multiple examinations, may also be the reason for the large amount of data missing.

Finally, earlier onset of ERT probably leads to a better disease course. However, the beneficial effect of
HRQoL
Disease progression impairs HRQoL in patients with MPS IVA. The median score of HAQ in the present study was 2.12; as HAQ scores can range between 0 (no disability) and 3 (maximum disability) [22], this result shows that patients with MPS IVA had an important disability. Moreover, as we confirmed in our study, HRQoL is worse in patients with the intermediate or classical phenotypes. Many factors contribute to a poor HRQoL: mobility, endurance, problems performing ADL, dependence on caregivers, frequent surgical interventions, fatigue and pain. Maintaining functionality and mobility, as well as pain control, will probably improve HRQoL in patients with MPS IVA [21].

Unemployment is related to a poorer HRQoL. Only 15% of our patients had a job, and only one patient worked full-time. In an international study in patients with MPS IVA, HRQoL was statistically significantly better in employed patients [22]. This difference could be due not only to higher psychological wellness, but also to a better physical state.

In this study, HRQoL, as measured by the HAQ score, was higher in patients treated with elosulfase alfa than in those not treated with ERT. Because of the small number of patients, we did not perform any statistical analysis, but we could hypothesise that ERT improved mobility, and hence HRQoL. A further comparison of 6MWT results in a larger number of ERT treated and untreated patients would be necessary.

It is recommended that the disease burden be assessed each year. At the annual visit, the physician in charge should evaluate HRQoL, fatigue, ADL, pain severity, and use of wheelchair or walking aids [22]. In addition, psychological health deserves more attention and should be assessed regularly [24].

Study limitations
It was a multicentre retrospective study and some data were missing. Especially in older patients, some data were not recorded or were lost. Regarding diagnosis test, urinary GAGs, enzyme activity and GALNS mutations were not assessed in all patients. The reasons were that these test were not available or easily accessed when middle age or old patients were diagnosed. In addition, urinary GAGs were measured in different laboratories with different references values. Furthermore, available tests were not the same for all laboratories and hospitals.

Classification of patients as classical, intermediate and non-classical phenotypes is not current practice. However, as it is stated above, the disease should be considered as a continuum [7]. Moreover, this classification allowed a better comparison between patients. In addition, although height is not the only abnormality that could be assessed, it is an objective measure that reflects the severity of bone dysplasia. Other authors have also categorized patients in these three groups by height [3, 7, 9].

We did not analyse GAG levels because measurements were performed at different laboratories with different cut-off points and different measurement units. However, all laboratories were specialized centres that were validated for the study of the MPS IVA.

As for ERT, elosulfase alfa has been approved by the Spanish Agency of Medicines and Medical Devices for the treatment of MPS IVA, but it is not yet on the market in Spain. Therefore, access to ERT is limited and only seven patients in the study received elosulfase alfa, all them on compassionate use.

Conclusions
Despite the limitations of a retrospective study, we were able to assess many variables. We therefore believe that our results are representative of the clinical status of adult patients with MPS IVA in Spain. Our study contributes to a better knowledge of the real-world clinical evolution of patients with MPS IVA into adulthood. The impaired mobility, hearing loss, pain, and poor HRQoL experienced by patients with MPS IVA demand the combined efforts of multidisciplinary teams. Future studies of the correlation between genotype and phenotype, as well as studies of biomarkers to evaluate disease progression and response to treatment, will help to provide better healthcare for patients with MPS IVA.

Methods
We conducted an observational, retrospective, descriptive study of adult patients with MPS IVA in Spain. Patients were included if they were aged 16 years or older, had been diagnosed with MPS IVA, and were being followed at Spanish reference centres for inherited metabolic diseases. Diagnosis of MPS IVA was based in clinical criteria and GAGs, enzyme activity and/or genetic study. Exclusion criteria were being unable to access medical records; not being willing to participate in the study.

We developed a questionnaire that included demographic, diagnostic and clinical variables. Sex, age, consanguinity, and family history were the main demographic variables, while the diagnostic variables included age at diagnosis, weight and length at birth, GAG levels in urine, and enzyme activity and/or molecular analysis. The clinical variables were phenotype, skeletal abnormalities, myelopathy (yes/no), history of neurosurgery,
The datasets used and/or analysed during the current study are available from BioMarin Pharmaceuticals España SL. funded the writing of this paper. All authors contributed extensively to the work presented in this paper. QFP received honoraria for lectures from the Takeda Pharmaceutical Company (Takeda), Sanofi Genzyme, Viflafo International (Vitafo), and BioMarin Pharmaceutical Inc. (BioMarin). GPM received honoraria for lectures and/or consulting and travel support from Takeda, Sanofi, BioMarin, Amicus Therapeutics (Amicus), Kyowa Kirin International, Alexson Pharmaceuticals (Alexion) and Vitafo. MIA received research support from Takeda, Sanofi Genzyme, Amicus, Kaleido, and Vitafo, and fees from Sanofi Genzyme, Takeda, Alexion, and Amicus for participation in their respective registries. EGN received research and meeting support from BioMarin, Sanofi Genzyme, Takeda, and Alnylam Pharmaceuticals. DMM received travel grants from Amicus, Sanofi and Takeda.

Statistics
We performed a descriptive analysis using SPSS software v. 21 (IBM, New York, NY, USA).

Abbreviations
6MWT: Six-minute walk test; ADL: Activities of daily living; ERT: Enzyme replacement therapy; GAG: Glycosaminoglycan, HAQ: Health assessment questionnaire; HRQoL: Health-related quality of life; MPS: Mucopolysaccharidosis.

Acknowledgements
Writing and editorial assistance were provided by Content Ed Net (Madrid, Spain).

Authors’ contributions
All authors contributed extensively to the work presented in this paper. QFP and MCM contributed to the conception, design, acquisition, analysis and interpretation of data, and drafting and revision of the manuscript. All the other authors contributed to the acquisition of data, and drafting, reviewing and or revising the manuscript. All authors have approved its submission.

Funding
BioMarin Pharmaceuticals España SL funded the writing of this paper.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The study was approved by the Ethics Committee of the University Hospital 12 de Octubre, Madrid. In addition, the study was conducted in accordance with the Declaration of Helsinki [28], the International Conference on Harmonization Guideline for Good Clinical Practice [29], and the Spanish regulations. All patients were given information about the study both verbally and in writing, and all gave informed consent before entering the study.

Consent for publication
Not applicable.

Competing interests
POF, EMH, EAC, SGM, JBA, RCS, EGS, MTG and MALR have no competing interests. MMC received honoraria for lectures from the Takeda Pharmaceutical Company (Takeda), Sanofi Genzyme, Viflafo International (Vitafo), and BioMarin Pharmaceutical Inc. (BioMarin). GPM received honoraria for lectures and/or consulting and travel support from Takeda, Sanofi, BioMarin, Amicus Therapeutics (Amicus), Kyowa Kirin International, Alexson Pharmaceuticals (Alexion) and Vitafo. MIA received research support from Takeda, Sanofi Genzyme, Amicus, Kaleido, and Vitafo, and fees from Sanofi Genzyme, Takeda, Alexion, and Amicus for participation in their respective registries. EGN received research and meeting support from BioMarin, Sanofi Genzyme, Takeda, and Alnylam Pharmaceuticals. DMM received travel grants from Amicus, Sanofi and Takeda.

Author details
1Unidad de Enfermedades Metabólicas Hereditarias, Servicio de Pediatría, Hospital Universitario 12 de Octubre, CSUR Enfermedades Metabólicas, MetabERN, Instituto de Investigación Sanitaria Hospital 12 de octubre (imas12), CIBERER, Madrid, Spain. 2Servicio de Medicina Interna, CSUR Enfermedades Metabólicas, MetabERN, Instituto de Investigación Sanitaria Hospital 12 de octubre (imas12), Hospital Universitario 12 de Octubre, Madrid, Spain. 3Sección de Genética Médica, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain. 4CIBERER (ISCIII), Madrid, Spain. 5Division of Rare Diseases, Reference Center for Hereditary Metabolic Disorders (CSUR, MetabERN, MetabXUEC), University Hospital Vall d’Hebron, Barcelona, Spain. 6Lysosomal Storage Disorders Unit, The Royal Free Hospital NHS Foundation Trust and University College London, London, UK. 7Unidad de Enfermedades Autoinmunes y Minoritarias, Servicio de Medicina Interna, Hospital Virgen del Rocio, Sevilla, Spain. 8Unidad de Gastroenterología y Nutrición Infantil, Grupo IMIB Multidisciplinary Pediatric, Hospital Regional Universitario de Málaga, Málaga, Spain. 9Unidad de Diagnóstico y Tratamiento de Enfermedades Metabólicas Hereditarias, Hospital Clínico Universitario de Santiago, IDIS, MetabERN, CIBERER, Santiago de Compostela, Spain. 10Hospital Universitario La Fe, Valencia, Spain. 11Inborn Errors of Metabolism and Paediatric Neurology Unit, Paediatric Department, Hospital Universitario Germans Trias i Pujol, Badalona, Spain. 12Servicio de Medicina Interna, CSUR Enfermedades Metabólicas Hereditarias, Hospital Universitario Ramón y Cajal, Madrid, Spain.

Received: 19 February 2021   Accepted: 10 October 2021

References
1. Kubaski F, De Oliveira PF, Michelin-Tirelli K, Burin MG, Rojas-Málaga D, Brusius-Facchin AC, et al. Diagnosis of mucopolysaccharidoses. Diagnostics. 2020;10:172.
2. Filocamo M, Tomanin R, Bertola F, Morrone A. Biochemical and molecular analysis in mucopolysaccharidoses: what a paediatrician must know. Ital J Pediatr. 2018;44:35–45.
3. Hendriksz CJ, Harmatz P, Beck M, Jones S, Wood T, Lachman R, et al. Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA. Mol Genet Metab. 2013;110:54–64.
4. Montaña AM, Tomatsu S, Gottesman GS, Smith M, Orii T. International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007;30:165–74.

464 Quijada-Fraile et al. Orphanet J Rare Dis (2021) 16:464
5. Pajares S, Alcalde C, Couce ML, Del Toro M, González-Meneses A, Guillén E, et al. Molecular analysis of mucopolysaccharidosis type IVA (Morquio A) in Spain. Mol Genet Metab. 2012;106:196–201.

6. Peracha H, Sawamoto K, Averill L, Kecskemethy H, Theroux M, Thacker M, et al. Molecular genetics and metabolism, special edition: diagnosis. Diagnosis and prognosis of mucopolysaccharidosis IVA. Mol Genet Metab. 2018;125:18–37.

7. Tomatsu S, Montano A, Oikawa H, Rowan D, Smith M, Barrera L, et al. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment: a current review. Curr Pharm Biotechnol. 2011;12:931–43.

8. Hendriksz CJ, Parini R, AlSayed MD, Raiman J, Giugliani R, Solano Villarreal ML, et al. Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome. Mol Genet Metab. 2016;119:131–43.

9. Moisan L, Iannuzzi D, Maranda B, Campeau PM, Mitchell JJ. Clinical characteristic of patients from Quebec, Canada, with Morquio A syndrome: a longitudinal observational study. Orphanet J Rare Dis. 2020;15:1–11.

10. Couce ML, del Toro M, García-Jiménez MC, Gutierrez-Solana L, Hermita-Amejeiras A, López-Rodríguez M, et al. Transition from pediatric care to adult care for patients with mucopolysaccharidosis. Rev Clinica Española (English Ed). 2018;218:17–21.

11. Akyol MU, Alden TD, Amantino H, Ashworth J, Berger KI, et al. Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance. Orphanet J Rare Dis. 2019;14:137.

12. López-Bastida J, Oliva-Moreno J, Linetová R, Serrano-Aguilar P. Social/ economic costs and health-related quality of life in patients with rare diseases in Europe. Eur J Heal Econ. 2016;17:1–5.

13. Bogart KR, Irvin VL. Health-related quality of life among adults with diverse rare disorders. Orphanet J Rare Dis. 2017;12:177.

14. Dünz VC, Tomatsu S, Monteño AM, Gottesman G, Gober MB, Mackenzie W, et al. Mucopolysaccharidosis IVA: correlation between genotype, phenotype and keratan sulfate levels. Mol Genet Metab. 2013;110:129–38.

15. Harmatz P, Mengel KE, Giugliani R, Valayannopoulos V, Lin S-P, Parini R, et al. The Morquio A clinical assessment program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Mol Genet Metab. 2013;109:54–61.

16. Pintos-Morell G, Blasco-Alonso J, Couce ML, Gutiérrez-Solana LG, Guillén-Navarro E, O’Callaghan M, et al. Elosulfase alfa for mucopolysaccharidosis type IVA: real-world experience in 7 patients from the Spanish Morquio-A early access program. Mol Genet Metab Rep. 2018;15:116–20.

17. Hughes D, Guigliani R, Guffon N, Jones SA, Mengel KE, Parini R, et al. Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa. Orphanet J Rare Dis. 2017;12:98.

18. Harmatz PR, Mengel E, Geberhiwot T, Muschol N, Hendriksz CJ, Burton BK, et al. Impact of elosulfase alfa in patients with Morquio A syndrome who have limited ambulation: an open-label, phase 2 study. Am J Med Genet A. 2017;173:375–83.

19. Hendriksz C, Santra S, Jones SA, Geberhiwot T, Jesaitis L, Long B, et al. Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5 years of treatment. Mol Genet Metab. 2018;123:479–87.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.